An Official Website of the United States Government
Company Information:
Name:
NANOTHERAPEUTICS, INC.
Address:
13859 Progress Blvd.
ALACHUA, FL
ALACHUA, FL
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
(386) 462-9663
Award Totals:
Award List:
N/A
Award Year / Program / Phase:
2000 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
James Talton
Award Amount:
$98,000.00
N/A
Award Year / Program / Phase:
2000 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
James D. Talton
Award Amount:
$98,000.00
N/A
Award Year / Program / Phase:
2000 / SBIR / Phase I
Agency:
NASA
Principal Investigator:
James D. Talton, Ph.D., President
Award Amount:
$70,000.00
Novel Dry-Powder Coatings for Low-G Inhalation Therapy
Award Year / Program / Phase:
2001 / SBIR / Phase II
Agency:
NASA
Principal Investigator:
James 1. Ph.D., President
Award Amount:
$538,071.00
Abstract:
Currently, dry-powder inhalers (DPI) are used to deliver various drugs to the lungs for localized or systemic delivery. Although current inhaled formulations are adequate for pulmonary drug therapy under normal gravity, inhalation therapies on earth and potentially in space are plagued by low… More
Novel Dry-Powder Coatings for Low-G Inhalation Therapy
Award Year / Program / Phase:
2001 / SBIR / Phase I
Agency:
NASA
Principal Investigator:
James 1. Ph.D., President
Award Amount:
$0.00
Abstract:
Currently, dry-powder inhalers (DPI) are used to deliver various drugs to the lungs for localized or systemic delivery. Although current inhaled formulations are adequate for pulmonary drug therapy under normal gravity, inhalation therapies on earth and potentially in space are plagued by low… More
Oral Therapy using Anti-Oxidants for Alzheimer's Disease
Award Year / Program / Phase:
2004 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Barbel Eppler
Award Amount:
$100,816.00
Abstract:
DESCRIPTION (provided by applicant): Nanotherapeutics proposes to evaluate oral taurine therapy for Alzheimer's disease (AD). AD, the most common form of dementia among older people, affects over 4 million Americans. It requires full-time care in the end stages and is a significant financial burden… More
ORAL BUPRENORPHINE NANOPARTICLE FORMULATION
Award Year / Program / Phase:
2004 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
James Talton
Award Amount:
$98,838.00
Technologies to Defeat Improvised Explosive Devices (IED's)
Award Year / Program / Phase:
2004 / SBIR / Phase I
Agency / Branch:
DOD / NAVY
Principal Investigator:
James Talton, President and CEO
Award Amount:
$99,745.00
Abstract:
In this Phase I SBIR Proposal, Nanotherapeutics, Inc. proposes to demonstrate the improved proximity detection of hexamethylene triperoxidediamine (HMTD) and triacetone triperoxide (TATP) explosives using its proprietary NanobreathTM preconcentrator and 4-SAW array. The NanobreathTM 4-SAW Array, a… More
Antimicrobial Bone Graft Substitute
Award Year / Program / Phase:
2005 / SBIR / Phase I
Agency / Branch:
DOD / ARMY
Principal Investigator:
James D. Talton, President and CEO
Award Amount:
$69,938.00
Abstract:
In this Phase I SBIR project, Nanotherapeutics proposes to utilize its proprietary particle delivery systems to develop an injectable bone paste formulation incorporating an anti-microbial (PHMB) as a bone graft substitute. A solution-based system, GraftonT (Osteotech) and, recently, a dry… More
ORAL BUPRENORPHINE NANOPARTICLE FORMULATION
Award Year / Program / Phase:
2005 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
James Talton
Award Amount:
$775,506.00
Technologies to Defeat Improvised Explosive Devices (IED's)
Award Year / Program / Phase:
2006 / SBIR / Phase II
Agency / Branch:
DOD / NAVY
Principal Investigator:
James D. Talton, CEO
Award Amount:
$940,875.00
Abstract:
The overall goal of this Phase II project is to develop the Nanobreathr detection system for proximity detection of explosives at 50 meters, and specifically detection of peroxide improvised explosive devices (IED's) such as TATP and HMTD. Pentagon statistics show that about half the U.S. battle… More
ORAL BUPRENORPHINE NANOPARTICLE FORMULATION
Award Year / Program / Phase:
2008 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Award Amount:
$116,660.00
Abstract:
Not Available
Development of A Synthetic Typhoid Fever Vaccine as A Substitution of Vi Vaccine
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Yawei Ni
Award Amount:
$595,945.00
Abstract:
DESCRIPTION (provided by applicant) Typhoid fever is a major cause of morbidity worldwide with an estimated incidence of 16 to 33 million infections and 500,000 to 600,000 deaths annually. It is caused by Salmonella typhi (S. typhi). The Vi capsular polys
accharide of S. typhi is the protective… More
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine
Award Year / Program / Phase:
2011 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
James F. Kirk – 386-462-9663
Award Amount:
$578,711.00
Abstract:
DESCRIPTION (provided by applicant): Noroviruses are a group of enteropathogenic viruses belonging to the taxonomic family Caliciviridae, which causes approximately 90% of epidemic non-bacterial outbreaks of gastroenteritis around the world and may be responsible for 50% of all foodborne outbreaks… More